Given the significant heterogeneity among HER2-positive breast cancers, relying on a single predictive biomarker is likely to be challenging and instead we anticipate that future prognostic models will integrate multiple variables to guide treatment decision-making [24]. The gene discussed is ERBB2; the disease is breast cancer.